

# Antibiotics

Containing the  
Beta-Lactam Structure I

Editors: A. L. Demain and N. A. Solomon



Springer-Verlag  
Berlin Heidelberg New York Tokyo

# Antibiotics

## Containing the Beta-Lactam Structure

### Part I

#### Contributors

E. P. Abraham · Y. Aharonowitz · C. Ball · B. G. Christensen  
A. L. Demain · R. P. Elander · R. Kirby · J. F. Martin · R. D. Miller  
D.-G. Mou · N. Neuss · T. N. Salzmann · E. O. Stapley · A. Tomasz  
S. B. Zimmerman

#### Editors

A. L. Demain and N. A. Solomon



Springer-Verlag Berlin Heidelberg New York Tokyo 1983

Professor Dr. ARNOLD L. DEMAIN  
Ms. NADINE A. SOLOMON  
Fermentation Microbiology Laboratory  
Department of Nutrition and Food Science  
Massachusetts Institute of Technology  
Cambridge, MA 02139/USA

With 83 Figures

ISBN 3-540-12107-2 Springer-Verlag Berlin Heidelberg New York Tokyo  
ISBN 0-387-12107-2 Springer-Verlag New York Heidelberg Berlin Tokyo

Library of Congress Cataloging in Publication Data. Main entry under title: Antibiotics containing the beta-lactam structure. (Handbook of experimental pharmacology; v. 67, pt. 1-) Includes index. 1. Antibiotics - Synthesis. 2. Beta-lactamases. 3. Fungi - Genetics. [DNLM: 1. Antibiotics - Pharmacodynamics. 2. Beta-lactamases - Pharmacodynamics. W1 HA51L v. 67/QV 350 A62935] QP905.H3 vol. 67, pt. 1, etc. 615'.1s 82-19689 [QD375] [547.7'6]

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use, a fee is payable to "Verwertungsgesellschaft Wort", Munich.

© by Springer-Verlag Berlin Heidelberg 1983  
Printed in Germany.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature.

Typesetting, printing, and bookbinding: Brühlsche Universitätsdruckerei Giessen  
2122/3130-543210

## Preface

It is quite amazing that the oldest group of medically useful antibiotics, the  $\beta$ -lactams, are still providing basic microbiologists, biochemists, and clinicians with surprises over 50 years after Fleming's discovery of penicillin production by *Penicillium*. By the end of the 1950s, the future of the penicillins seemed doubtful as resistant strains of *Staphylococcus aureus* began to increase in hospital populations. However, the development of semisynthetic penicillins provided new structures with resistance to penicillinase and with broad-spectrum activity. In the 1960s, the discovery of cephalosporin C production by *Cephalosporium* and its conversion to valuable broad-spectrum antibiotics by semisynthetic means excited the world of chemotherapy. In the early 1970s, the 40-year-old notion that  $\beta$ -lactams were produced only by fungi was destroyed by the discovery of cephamycin production by *Streptomyces*. Again this basic discovery was exploited by the development of the semisynthetic cefoxitin, which has even broader activity than earlier  $\beta$ -lactams. Later in the 1970s came the discoveries of nocardicins from *Nocardia*, clavulanic acid from *Streptomyces*, and the carbapenems from *Streptomyces*. Now in the 1980s we learn that  $\beta$ -lactams are produced even by unicellular bacteria and that semisynthetic derivatives of these monobactams may find their way into medicine. Indeed, the future of the prolific  $\beta$ -lactam family seems brighter with each passing decade.

Considering the level of excitement in this area, we felt that this would be the right time for the leaders in the field to survey past and present research, development, and clinical applications of  $\beta$ -lactams and prospects for future progress. We were pleasantly surprised that so many busy people agreed to give up their time to contribute to this project. The result is this volume in two parts describing all aspects of  $\beta$ -lactam antibiotics.

Cambridge

ARNOLD L. DEMAIN  
NADINE A. SOLOMON

## List of Contributors

Sir E. P. ABRAHAM, Sir William Dunn School of Pathology, University of Oxford,  
South Parks Road, Oxford OX1 3RE, Great Britain

Dr. Y. AHARONOWITZ, Department of Microbiology, The George S. Wise Faculty  
of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel

Dr. C. BALL, Squibb Institute for Medical Research, Biological Process  
Development, E.R. Squibb & Sons, Inc., Georges Road, New Brunswick,  
NJ 08903/USA

Dr. B. G. CHRISTENSEN, Merck Sharp & Dohme Research Laboratories,  
P.O. Box 2000, Rahway, NJ 07065/USA

Professor Dr. A. L. DEMAİN, Fermentation Microbiology Laboratory, Department  
of Nutrition and Food Science, Massachusetts Institute of Technology,  
Cambridge, MA 02139/USA

Dr. R. P. ELANDER, Fermentation Research and Development, Bristol-Myers Co.,  
Industrial Division, P.O. Box 657, Syracuse, NY 13201/USA

Dr. R. KIRBY, University of Cape Town, Department of Microbiology,  
Rondebosch 7700, South Africa

Professor Dr. J. F. MARTIN, Department of Microbiology, Faculty of Biology,  
University of León, León, Spain

Dr. R. D. MILLER, Eli Lilly & Co., P.O. Box 685, Lafayette, IN 47902/USA

Dr. D.-G. MOU, Research Laboratories, Eastman Kodak Company, Kodak Park,  
Rochester, NY 14650/USA

Dr. N. NEUSS, Lilly Research Laboratories, Eli Lilly & Co., Indianapolis,  
IN 46205/USA

Dr. T. N. SALZMANN, Merck Sharp & Dohme Research Laboratories,  
Rahway, NJ 07065/USA



Dr. E. O. STAPLEY, Merck Sharp & Dohme Research Laboratories, Department of Basic Microbiological Research, P.O. Box 2000, Rahway, NJ 07065/USA

Dr. A. TOMASZ, The Rockefeller University, 1230 York Avenue, New York, NY 10021/USA

Dr. S. B. ZIMMERMAN, Merck Sharp & Dohme Research Laboratories, Department of Basic Microbiological Research, P.O. Box 2000, Rahway, NJ 07065/USA

# Contents

## CHAPTER 1

### History of $\beta$ -Lactam Antibiotics. E. P. ABRAHAM

A. The Past Fifty Years . . . . .	1
I. Fleming's Discovery . . . . .	1
II. Discovery of the Therapeutic Power of Penicillin in Systemic Infections . . . . .	2
III. Large-Scale Production . . . . .	2
IV. Wartime Interest in Penicillin in Europe and Japan . . . . .	3
V. Isolation, Structure, and Synthesis . . . . .	4
VI. Penicillin-Resistant Bacteria . . . . .	5
VII. 6-Aminopenicillanic Acid and New Penicillins . . . . .	6
VIII. 7-Aminocephalosporanic Acid and the Cephalosporins . . . . .	7
IX. New $\beta$ -Lactam Compounds . . . . .	9
X. Biosynthesis . . . . .	9
XI. Mode of Action and Resistance . . . . .	10
B. The Future . . . . .	11
References . . . . .	13

## CHAPTER 2

### Mode of Action of $\beta$ -Lactam Antibiotics – A Microbiologist's View. A. TOMASZ. With 17 Figures

A. Introduction . . . . .	15
I. Mode of Action Studies: Benefits for Basic and Applied Sciences . . . . .	15
II. Mode of Action of Penicillin: A Multilevel Problem . . . . .	16
B. Journey of the Extracellular Antibiotic to the Intracellular Targets . . . . .	17
I. Extracellular Barriers . . . . .	17
II. Barriers in the Bacterial Envelope . . . . .	17
III. The Outer Membrane of Gram-Negative Bacteria . . . . .	18
IV. The End of the Journey: Arrival at the Plasma Membrane . . . . .	19
C. The Biochemical Targets of $\beta$ -Lactam Antibiotics . . . . .	20
I. Selective Toxicity of $\beta$ -Lactams . . . . .	20
II. Localization of Radioactively Labeled Penicillin in Bacteria . . . . .	23
III. Morphological and Biochemical Effects of Penicillin . . . . .	23
IV. Penicillin-Sensitive Enzymes . . . . .	25

1. Molecular Basis of Specificity . . . . .	26
2. Studies with Model Substrates and Model Enzymes . . . . .	29
V. Penicillin-Binding Proteins (PBPs) . . . . .	35
1. Enzymatic Activity of PBPs with Model Substrates . . . . .	35
2. Penicillin Binding and Inactivation of Enzyme Activity . . . . .	36
3. Localization of PBPs . . . . .	37
4. Labeling of PBPs in Live, Growing Bacteria . . . . .	38
5. Selective Affinity of PBPs for Various $\beta$ -Lactams . . . . .	40
6. Selective Morphological Effects . . . . .	41
VI. Penicillin-Sensitive Enzymes in Cell Wall Synthesis . . . . .	46
1. Penicillin-Sensitive Enzymes as PBPs . . . . .	50
D. Physiological Consequences of $\beta$ -Lactam Inhibition . . . . .	51
I. Search for the Killing Targets . . . . .	51
II. Labeling of PBPs in Live Bacteria . . . . .	53
III. In Vivo Labeling of PBPs in Pneumococci . . . . .	54
IV. Dynamic Experiments with the Labeling of PBPs in Growing Pneumococci . . . . .	55
V. PBP Alterations in Intrinsically $\beta$ -Lactam-Resistant Bacteria . . . . .	57
VI. Several Physiologically Important PBPs in Pneumococci . . . . .	57
E. Variations in the Physiological Effects of Penicillins . . . . .	60
I. The Single Target – Unbalanced Growth Model . . . . .	60
II. From Inhibited Enzyme to Inhibited Target Cell . . . . .	61
III. Inhibition of Growth, Loss of Viability, Lysis . . . . .	61
IV. The PBPs of Penicillin-Tolerant Bacteria . . . . .	63
V. Penicillin-Induced Death, Without Lysis (Group A Streptococci) . . . . .	64
VI. Reversible Growth-Inhibitory Effect of Penicillin . . . . .	64
VII. Penicillin Tolerance in Bacteria with Suppressed Murein Hydrolase Activity . . . . .	66
VIII. Penicillin-Induced Lysis and Death in <i>E. coli</i> . . . . .	68
IX. How and Why Does Penicillin Cause Cell Wall Degradation? . . . . .	69
X. Possible Causes of Penicillin-Induced Cell Wall Degradation in <i>E. coli</i> . . . . .	71
XI. Penicillin-Induced Lysis and Natural Inhibitors of Autolysis . . . . .	72
XII. Attempts to Define the Events Responsible for the Triggering of Autolytic Activity in Pneumococci . . . . .	73
F. Environmental Factors That Modulate the Antibacterial Effects of Penicillin . . . . .	74
I. Protection Against the Lytic (and Cidal) Effects by Alteration of the pH of the Medium . . . . .	74
II. The Effect of Exogenous Murein Hydrolases on Penicillin-Treated Tolerant Bacteria . . . . .	75
III. Synergistic Bactericidal Action of Penicillin and Human Polymor- phonuclear White Blood Cells (PMN) . . . . .	75
IV. Inhibition of Penicillin-Induced Lysis by Extracellular Lipids and Lipoteichoic Acids . . . . .	75
V. Penicillin-Induced Release of Cell Surface Components into the Medium . . . . .	76



VI. Phenotypic Tolerance in Nongrowing Cells . . . . .	76
G. Conclusion . . . . .	78
References . . . . .	84

## CHAPTER 3

**Strain Improvement and Preservation of  $\beta$ -Lactam-Producing Microorganisms.**

R. P. ELANDER. With 9 Figures

A. Introduction . . . . .	97
B. Distribution of $\beta$ -Lactam Antibiotics and Related Metabolites in Nature . . . . .	99
C. Strain Improvement Programs in Commercially Important $\beta$ -Lactam Fermentation Organisms . . . . .	109
I. Mutation and Enhanced Penicillin Formation in <i>P. chrysogenum</i> . . . . .	110
II. Mutagenesis and Yield Improvement in the Cephalosporin C Organism, <i>Acremonium chrysogenum</i> . . . . .	112
III. Rational Screening or Selection for Improved Mutants or Mutants Producing Modified $\beta$ -Lactam Antibiotics . . . . .	114
1. Mutants Screened Directly on Agar Plates . . . . .	115
2. Selection of Mutants for Resistance to Toxic Antibiotic Precursors or Analogs of Precursors . . . . .	115
3. Selection of Mutants Resistant to Metallic Ions . . . . .	116
4. Isolation of Specific Morphological Mutants of <i>A. chrysogenum</i> . . . . .	117
5. Use of Auxotrophic Strains or Revertants of Auxotrophic Strains . . . . .	117
6. Mutational Biosynthesis and New Biosynthetic $\beta$ -Lactams . . . . .	118
D. Actinomycetes Producing New $\beta$ -Lactam Antibiotics . . . . .	119
I. Cephamycins (7-Methoxycephalosporins) . . . . .	119
1. Cephamycin Fermentations . . . . .	121
2. Improvement in Strains of <i>Nocardia lactamdurans</i> . . . . .	123
II. Nocardicins . . . . .	123
1. Strain Improvement . . . . .	124
2. Nocardicin A Fermentation . . . . .	126
III. Clavulanic Acid . . . . .	129
IV. Hydroxyethylclavam . . . . .	129
V. Thienamycin . . . . .	130
VI. Olivanic Acids . . . . .	130
VII. PS-5 and Related Carbapenems . . . . .	131
VIII. C-19393 S <sub>2</sub> and H <sub>2</sub> . . . . .	133
IX. Carpetimycins . . . . .	134
E. Unicellular Bacteria Producing Sulfazecins and Related Structures . . . . .	134
F. Maintenance and Long-Term Preservation of Strains of <i>Penicillium chrysogenum</i> and <i>Acremonium chrysogenum</i> . . . . .	135
I. Studies with <i>P. chrysogenum</i> . . . . .	136
II. Studies with <i>A. chrysogenum</i> . . . . .	138
References . . . . .	140

## CHAPTER 4

**Genetics of  $\beta$ -Lactam-Producing Fungi.** C. BALL. With 4 Figures

A. Introduction . . . . .	147
B. <i>Aspergillus nidulans</i> . . . . .	147
I. The Parasexual Cycle . . . . .	148
II. The Genetics of Penicillin Production . . . . .	149
C. <i>Penicillium chrysogenum</i> . . . . .	150
I. Early Studies . . . . .	151
II. Later Studies . . . . .	153
D. <i>Cephalosporium acremonium</i> . . . . .	157
E. Recombination Between Naturally Incompatible Fungi . . . . .	159
References . . . . .	160

## CHAPTER 5

**Genetics of  $\beta$ -Lactam-Producing Actinomycetes.** R. KIRBY. With 4 Figures

A. Introduction . . . . .	163
B. $\beta$ -Lactam Antibiotics and the Actinomycetales . . . . .	165
C. <i>Streptomyces</i> Genetics . . . . .	167
I. Plasmids in <i>Streptomyces</i> . . . . .	171
II. Plasmids in $\beta$ -Lactam-Producing <i>Streptomyces</i> . . . . .	175
D. Antibiotic Production in Actinomycetes . . . . .	176
I. Unstable Genetic Systems in <i>Streptomyces</i> Which do not Involve Plasmids . . . . .	177
II. Protoplast Fusion and <i>Streptomyces</i> . . . . .	178
III. Transformation and <i>Streptomyces</i> . . . . .	179
IV. Restriction and Modification Systems in <i>Streptomyces</i> . . . . .	180
V. Genetic Engineering and <i>Streptomyces</i> . . . . .	181
E. The Genetics of $\beta$ -Lactam Antibiotics and the Future . . . . .	183
References . . . . .	184

## CHAPTER 6

**Biosynthesis of  $\beta$ -Lactam Antibiotics.** A. L. DEMAIN. With 6 Figures

A. Introduction . . . . .	189
B. Hydrophobic $\beta$ -Lactam Antibiotics . . . . .	191
I. Biosynthetic Precursors . . . . .	191
II. Terminal Biosynthetic Reaction . . . . .	197
C. Hydrophilic $\beta$ -Lactam Antibiotics . . . . .	198
I. Early Biosynthetic Steps . . . . .	200
II. Formation of the Bicyclic Ring Structure . . . . .	201
III. Epimerization of Isopenicillin N to Penicillin N . . . . .	203
IV. Conversion of Penicillin N to Cephalosporin C . . . . .	203
V. Formation of Additional Cephalosporins by Actinomycetes . . . . .	206
D. Antibiotic Production by Pairs of Blocked Mutants . . . . .	208

E. Novel $\beta$ -Lactam Antibiotics . . . . .	208
I. Fungal Products . . . . .	208
II. Actinomycete Products . . . . .	213
III. Products of Unicellular Bacteria . . . . .	217
References . . . . .	220

## CHAPTER 7

### **Regulation of Biosynthesis of $\beta$ -Lactam Antibiotics. J. F. MARTIN and Y. AHARONOWITZ. With 5 Figures**

A. Introduction . . . . .	229
B. Carbon Catabolite Regulation . . . . .	229
I. Regulation of the Biosynthesis of Fungal $\beta$ -Lactams by Glucose . . . . .	229
II. Carbon Catabolite Regulation of the Biosynthesis of $\beta$ -Lactams by Actinomycetes . . . . .	231
C. Nitrogen Metabolite Regulation . . . . .	232
D. Regulation at the Level of Sulfur Metabolism . . . . .	235
E. Lysine Metabolism and Antibiotic Biosynthesis . . . . .	239
I. Control by Lysine of the Biosynthesis of Fungal $\beta$ -Lactams . . . . .	239
II. Lysine Effect in Actinomycetes . . . . .	242
F. Control of $\beta$ -Lactam Specific Enzymes at the Level of Secondary Metabolism . . . . .	245
I. Possible Control Mechanisms at the Tripeptide Synthetase Level . . . . .	246
1. Control of the Cyclization of the Tripeptide . . . . .	246
2. Control of the Ring-Expansion System . . . . .	247
II. Control of Penicillin Acyltransferase . . . . .	247
III. Regulation of Late Enzymes in Cephalosporin and Cephamycin Biosynthesis . . . . .	248
G. End-Product Regulation . . . . .	249
H. Summary and Future Outlook . . . . .	250
References . . . . .	250

## CHAPTER 8

### **Biochemical Engineering and $\beta$ -Lactam Antibiotic Production**

D.-G. MOU. With 13 Figures

A. Introduction . . . . .	255
B. Penicillin Fermentation – Current Status . . . . .	257
C. Growth Monitoring and Control – Method of Approach . . . . .	263
I. Formulation of a Realistic Medium . . . . .	263
II. Growth Monitoring . . . . .	264
1. Empirical Correlations . . . . .	264
2. Physiological Model – Respiratory Quotient . . . . .	264
3. Carbon-Balancing Equation . . . . .	266
III. Growth Control in Fed-Batch Fermentation . . . . .	269

1. Control Strategy . . . . .	269
2. Manipulation of Cell Growth Curve by On-Line Controlled Glucose Feed . . . . .	270
D. Effect of Growth on Penicillin Production . . . . .	273
E. Effect of the Use of Corn-Steep Liquor . . . . .	275
F. Maintenance Demand as a Fermentation Variable . . . . .	277
I. Calculation of Maintenance Demand for Sugar . . . . .	277
II. Reduction of Maintenance Demand Through Strain Improvement .	278
III. Reduction of Maintenance Demand Through Process Improvement and Its Implication . . . . .	278
G. Overall Conversion Yield of Glucose to Penicillin- $\bar{Y}_{P/S}$ . . . . .	280
H. Summary . . . . .	281
I. New Insight into Fermentation Kinetics . . . . .	281
II. Proposal of a Working Methodology for Process Improvement .	282
References . . . . .	283

## CHAPTER 9

**Screening for New  $\beta$ -Lactam Antibiotics.** S. B. ZIMMERMAN  
and E. O. STAPLEY. With 7 Figures

A. Introduction . . . . .	285
B. Rationale for Screening of $\beta$ -Lactam Antibiotics . . . . .	287
I. Mode of Action . . . . .	287
II. Potency and Spectrum . . . . .	288
III. Chemical Alterability . . . . .	288
IV. Potentiation of Other Antibiotics . . . . .	289
C. Finding $\beta$ -Lactam-Producing Microorganisms . . . . .	289
I. Discovery of Fungi as Producers of $\beta$ -Lactams . . . . .	289
II. Discovery of Actinomycetes as Producers of $\beta$ -Lactams . . . . .	289
1. World-Wide Search for Antibiotic-Producing Microorganisms .	290
2. Development of Culture Isolation Techniques . . . . .	290
III. Discovery of Bacteria as Producers of $\beta$ -Lactams . . . . .	291
D. Screening Systems Which Detect $\beta$ -Lactams . . . . .	291
I. Biospectrum and Physicochemical Data Comparisons . . . . .	291
1. Penicillin N . . . . .	293
2. Cephamycins . . . . .	293
II. $\beta$ -Lactamase Inhibition . . . . .	293
1. Clavulanic Acid . . . . .	293
2. Olivanic Acids . . . . .	294
3. PS-5, -6, and -7 . . . . .	294
4. Carpetimycins . . . . .	294
III. $\beta$ -Lactam Supersensitive Bacterial Mutants . . . . .	294
1. The Nocardicins . . . . .	294
2. Deacetoxycephalosporin C . . . . .	294
3. PS-5 . . . . .	295
4. Sulfazecin and Isosulfazecin . . . . .	295

IV. Screening for Bacterial Cell Wall Inhibitors . . . . .	295
1. Cephamycins, Epithienamycins, and Thienamycins . . . . .	295
2. Azureomycin . . . . .	295
V. Screening of Penicillin N-Producing Cultures . . . . .	295
1. Deacetoxycephalosporin C . . . . .	295
E. Future Trends . . . . .	296
F. A Hypothetical Screening Model . . . . .	296
References . . . . .	297

## CHAPTER 10

**High-Performance Liquid Chromatography of  $\beta$ -Lactam Antibiotics.**

R. D. MILLER and N. NEUSS. With 18 Figures

A. Introduction . . . . .	301
B. Penicillin Antibiotics . . . . .	303
I. 6-Aminopenicillanic Acid (6-APA) . . . . .	303
II. Amoxicillin (Clamoxyl) . . . . .	305
III. Ampicillin (Penbritin) . . . . .	305
IV. Carbenicillin . . . . .	305
V. Penicillin G . . . . .	306
VI. Penicillin V . . . . .	306
VII. Sulbenicillin . . . . .	307
VIII. Concluding Remarks . . . . .	307
C. Cephalosporin Antibiotics . . . . .	307
I. 7-Aminocephalosporanic Acid (7-ACA) . . . . .	308
II. Cefaclor . . . . .	308
III. Cefamandole . . . . .	308
IV. Cefazolin . . . . .	309
V. Cefoxitin . . . . .	309
VI. Ceftizoxime . . . . .	309
VII. Cephalexin . . . . .	310
VIII. Cephaloglycin . . . . .	310
IX. Cephaloridine . . . . .	310
X. Cephalosporin C . . . . .	311
XI. Cephalothin . . . . .	312
XII. Cephapirin . . . . .	312
XIII. Cephhradine . . . . .	312
XIV. Concluding Remarks . . . . .	313
D. Other $\beta$ -Lactam Compounds . . . . .	317
I. Nocardicin A and B . . . . .	317
II. Clavulanic Acid . . . . .	319
III. Thienamycin . . . . .	321
IV. Olivanic Acids . . . . .	321
E. Oxy- $\beta$ -Lactams . . . . .	322
F. Concluding Remarks . . . . .	325
References . . . . .	327



## CHAPTER 11

**Strategy in the Total Synthesis of  $\beta$ -Lactam Antibiotics.**

B. G. CHRISTENSEN and T. N. SALZMANN

A. Introduction . . . . .	329
B. $\beta$ -Lactam Closure . . . . .	329
C. 2+2 Annulations . . . . .	329
D. Monocyclic $\beta$ -Lactam Antibiotics . . . . .	330
E. Examples Involving Prior Construction of the Azetidinone . . . . .	330
F. Penicillin Total Synthesis – Sheehan . . . . .	331
G. Cefoxitin Total Synthesis – Merck . . . . .	333
H. Nocardicin Total Synthesis – Wasserman . . . . .	337
I. Total Synthesis of ( $\pm$ )-Clavulanic Acid – Beecham . . . . .	339
J. Cephalosporin C Total Synthesis – Woodward . . . . .	341
K. Penicillin Total Synthesis – Baldwin . . . . .	344
L. Synthesis of the Penem Nucleus – Woodward . . . . .	346
M. Total Synthesis of (+)-Thienamycin – Merck . . . . .	348
N. Conclusion . . . . .	352
References . . . . .	352

<b>Subject Index . . . . .</b>	<b>355</b>
--------------------------------	------------

# **Contents of Companion Volume 67, Part II**

## **CHAPTER 12**

### **Bacterial Enzymes Interacting with $\beta$ -Lactam Antibiotics**

N. H. GEORGOPAPADAKOU and R. B. SYKES. With 10 Figures

## **CHAPTER 13**

### **In Vitro and In Vivo Laboratory Evaluation of $\beta$ -Lactam Antibiotics**

A. K. MILLER

## **CHAPTER 14**

### **$\beta$ -Lactam Antibiotics: Structure-Activity Relationships**

J. R. E. HOOVER. With 8 Figures

## **CHAPTER 15**

### **Pharmacokinetics of $\beta$ -Lactam Antibiotics**

K. C. KWAN and J. D. ROGERS. With 28 Figures

## **CHAPTER 16**

### **Toxicology of $\beta$ -Lactam Antibiotics**

M. C. BROWNING and B. M. TUNE

## **CHAPTER 17**

### **Therapeutic Application of $\beta$ -Lactam Antibiotics**

J. V. URI and P. ACTOR

## **Subject Index**

## CHAPTER 1

# History of $\beta$ -Lactam Antibiotics

E. P. ABRAHAM

## A. The Past Fifty Years

### I. Fleming's Discovery

During the second half of the nineteenth century observations of the antagonism of fungi of the genus *Penicillium* to the growth of bacteria were recorded by JOHN TYNDALL, JOHN BURDON-SANDERSON, JOSEPH LISTER, T.H. HUXLEY, ERNEST DUCHESNE, who was a French medical student, and others. Whether any of these examples of microbial antagonism was due to the presence of penicillin is unknown. However that may be, they bore no fruit. It was not until 1929 that ALEXANDER FLEMING, in a paper from St. Mary's Hospital, London, introduced the term "penicillin" for an entity with well-defined antibacterial properties (FLEMING 1929).

While looking at plates that had been seeded with staphylococci and left on a laboratory bench during a vacation, Fleming noticed that one plate had been contaminated by a mold and that in the vicinity of this contaminant the bacteria were apparently undergoing lysis. He grew the mold (*Penicillium notatum*) in broth and showed that the resulting culture filtrate powerfully inhibited the growth of a number of gram-positive pathogenic bacteria and gram-negative cocci, but not that of gram-negative bacilli; and he decided to use the name penicillin for the more cumbersome phrase "mold broth filtrate."

The phenomenon seen by FLEMING is not easily reproducible in the laboratory, because penicillin brings about the lysis of growing staphylococci but not that of staphylococci in cultures that have reached the end of their growth. It appears that a period of cool weather allowed the *Penicillium* to form a large colony and produce penicillin before growth of the bacteria was completed as a result of a rise in the ambient temperature. FLEMING's great achievement lay in his flair for seizing on the unexpected, which he had revealed earlier in his discovery of lysozyme. He found that his penicillin was no more toxic than ordinary broth to a rabbit, a mouse, or the leukocyte and he tried it as a local antiseptic. But there is nothing to indicate that he ever envisaged that it could be injected into the blood stream to act as a chemotherapeutic agent in systemic infections. His interest focused on its use as a selective antibacterial agent in differential cultures.

FLEMING's two assistants, F. RIDLEY and S. R. CRADDOCK, prepared crude extracts of penicillin. In 1932 CLUTTERBUCK, LOVELL and RAISTRICK made an attempt to isolate penicillin, but abandoned it after finding that the antibacterial activity of the substance could readily be lost. Clearly no one imagined, at this time, that penicillin was of outstanding medical value. It must be remembered that the

therapeutic properties of the sulfonamides were then unknown and that the possibility of finding chemical substances that could cope with bacterial septicaemia was viewed with pessimism. Nevertheless, when the successful use of prontosil and sulfanilamide was revealed in 1935, no interest in penicillin was rekindled.

## II. Discovery of the Therapeutic Power of Penicillin in Systemic Infections

A second chapter in the history of penicillin began in 1938, when Professor H. W. FLOREY and Dr. E. B. CHAIN, in the Sir William Dunn School of Pathology at Oxford University, decided to make a systematic survey of the antibacterial substances known to be produced by microorganisms. This project was suggested by CHAIN during the course of discussions on these substances with FLOREY and it arose out of FLOREY's interest in lysozyme. It was motivated by scientific interest and not by the hope that such substances would prove to have medical value. Nevertheless, in 1939, after attempts to purify bactericidal substances produced by *P. notatum* and *Pseudomonas pyocyanea* had begun, the possibility that such substances might have clinical application was noted in a successful request to the Rockefeller Foundation for support.

The use of a solvent-transfer process for the purification of penicillin, suggested independently in Oxford by N. G. HEATLEY following its earlier unpublished use by L. B. HOLT at St. Mary's Hospital, led to the preparation of material that was not more than 1% pure. Between May and July 1940 FLOREY showed conclusively that this crude penicillin, given subcutaneously, could protect mice from otherwise fatal infections with the streptococcus or the staphylococcus. By this time, A. D. GARDNER, A. G. SANDERS, E. P. ABRAHAM and others had also begun to work on the penicillin project and a major effort was made to purify it further and produce enough material for a small clinical trial. The treatment in Oxford of five patients who were gravely ill with streptococcal or staphylococcal infections was carried out by FLOREY and C. M. FLETCHER early in 1941. The purity of the penicillin used varied from 0.3% to 7% and the supply was inadequate, even though it was supplemented by material recovered from the urine. Nevertheless, the results of this trial indicated that penicillin was not toxic to man and could control very severe infections.

## III. Large-Scale Production

In view of the wartime situation in Britain FLOREY and HEATLEY went to the United States in June 1941, with FLEMING's strain of *P. notatum* and in the hope that penicillin could be made there in larger quantities. Their visit was facilitated by the Medical Research Council and supported by the Rockefeller Foundation. Work on penicillin at Columbia University was already being done by DAWSON, HOBBS, MEYER and CHAFFEE. At the Northern Regional Research Laboratory (NRRL) in Peoria Dr. COGHILL suggested that the use of deep fermentation, rather than stationary surface culture, might facilitate commercial production. A. J. MOYER, who worked with HEATLEY, introduced the use of corn-steep liquor (which contained